Omega-3 fatty acids for dialysis vascular access outcomes in patients with chronic kidney disease

Medicine and Dentistry

• Chronic Kidney Disease 100%
• Supplementation 100%
• Omega-3 Fatty Acid 100%
• Vascular Access 100%
• Attributable Risk 100%
• Adverse Event 50%
• Arteriovenous Fistula 50%
• Cardiovascular System 37%
• End Stage Renal Disease 37%
• Placebo 37%
• Major Bleeding 37%
• Hemodialysis 25%
• Clinical Trial 12%
• Random Effects Model 12%
• Transplantation 12%
• Thrombosis 12%
• Gastrointestinal Bleeding 12%
• Randomized Controlled Trial 12%
• Stenosis 12%
• Sensation 12%
• Cognitive Bias 12%

Nursing and Health Professions

• Confidence Interval 100%
• Vascular Access 100%
• Chronic Kidney Failure 100%
• Omega-3 Fatty Acid 100%
• Supplementation 72%
• Attributable Risk 72%
• Arteriovenous Graft 54%
• Adverse Event 36%
• Arteriovenous Fistula 36%
• End Stage Renal Disease 27%
• Placebo 27%
• Hemodialysis 18%
• Bleeding 18%
• Pilot Study 9%
• Transplantation 9%
• Gastrointestinal Hemorrhage 9%
• Vascular Patency 9%
• Stenosis 9%
• Thrombosis 9%

Pharmacology, Toxicology and Pharmaceutical Science

• Adverse Event 100%
• Chronic Kidney Failure 100%
• Omega-3 Fatty Acid 100%
• Arteriovenous Fistula 100%
• End Stage Renal Disease 75%
• Placebo 75%
• Bleeding 50%
• Hemodialysis 50%
• Clinical Trial 25%
• Randomized Controlled Trial 25%
• Gastrointestinal Hemorrhage 25%
• Random Effects Model 25%
• Thrombosis 25%
• Stenosis 25%